The typical CAR-T treatment timeline in China spans 4 to 8 weeks from initial screening to discharge. This includes a 1-week evaluation, a 2-week manufacturing phase, and a 14-to-28-day inpatient monitoring period. Patients seeking rapid care can often access “Next-Day CAR-T” platforms in Shanghai, which reduce the car t cell therapy cost in china and manufacturing time significantly. Mayo Clinic describes CAR-T cell therapy as a process that involves collecting and modifying a patient’s own T-cells before reinfusing them — a multi-step journey that requires careful coordination at every phase.
nImportant: This article is general information, not medical advice, a treatment recommendation, or a statement that a particular product, hospital, clinical trial, appointment, price, or travel route is currently available. China Care is a non-clinical coordination service. Treating institutions and their clinicians decide whether they can review or accept a case, clinical suitability, treatment, risk, costs, language arrangements, and follow-up.
Clinical-trial participation is determined by the study team and protocol. China Care does not determine eligibility or present a trial as a guaranteed or default route.
Any cost or timing figure in this article is dated reference information, not a quotation or promise. The relevant institution confirms current medical charges, payment arrangements, availability, and timing.
Planning note
- Institutional review, manufacturing, admission, monitoring, and discharge timing vary by case and institution.
- No treatment date, manufacturing timeframe, admission duration, or travel documentation route should be assumed before direct institutional confirmation.
- Visa and entry decisions are made by the relevant authorities, not China Care.
Table of Contents
Phase 1: Remote Evaluation & Visa (Week 0)
Before booking your flight, you must clear the “Digital Gateway.” 2026 protocols emphasize remote verification to ensure international patients are fit for travel.
- Document Submission: You will provide PET-CT scans, IHC pathology reports, and recent blood work via secure channels (or WhatsApp).
- Institutional review: The relevant institution decides whether it can review a case and which records it requires.
- Travel documentation: Visa and entry requirements are determined by the relevant authorities and should be confirmed with the appropriate embassy, visa centre, immigration authority, and institution.
Phase 2: Admission & Cell Collection (Week 1)
Upon arrival in China, you are admitted to the hematology ward for the “Vein-to-Vein” starting point.
- Day 1–3: Baseline Tests: In-person screening to confirm organ function (Heart/Lung/Kidney).
- Day 4–5: Leukapheresis: This is the cell collection process. A machine filters T-cells from your blood and returns the rest. It takes about 3–5 hours and is generally painless. This step is the same procedure used in all FDA-approved CAR-T therapies and forms the biological foundation of the entire treatment.
Phase 3: Manufacturing & Bridging (Weeks 2–3)
While your T-cells are in the lab being “armed” with cancer-fighting receptors, you enter the waiting phase.
- Lab Engineering: In 2026, Gracell’s FasTCAR platform achieves next-day manufacturing — compressing the cell engineering step to within 24 hours, compared to the global standard of 1–6 weeks. The total treatment stay (leukapheresis through post-infusion monitoring) remains 4–6 weeks. China’s manufacturing speed advantage is visible in the active trial pipeline at ClinicalTrials.gov, where dozens of Chinese studies specifically investigate accelerated vector and cell engineering platforms.
- Bridging Therapy: If your tumor burden is high, doctors may administer low-dose chemotherapy to keep the cancer stable while the CAR-T cells are being manufactured.
For more on which hospitals offer the fastest manufacturing, see our guide to the Best CAR-T Cell Therapy Hospitals in China.
Phase 4: Infusion & Critical Monitoring (Weeks 4–6)
This is the most sensitive part of the car-t cell therapy treatment journey, as it requires intensive 24/7 nursing care.
- Conditioning (Days −3 to −1): You receive “lymphodepletion” chemotherapy to clear space for the new cells. NCCN guidelines for B-cell lymphomas specify lymphodepleting conditioning as a mandatory preparatory step before CAR-T infusion.
- The Infusion (Day 0): The modified CAR-T cells are infused back into your bloodstream.
- Inpatient Watch: Unlike the US, where outpatient infusion is common, China requires a 14-to-28-day hospital stay. Doctors monitor for Cytokine Release Syndrome (CRS) and neurological side effects (ICANS). MD Anderson Cancer Center identifies CRS and neurotoxicity as the two primary safety concerns requiring close inpatient observation after any CAR-T infusion.
Phase 5: Recovery & Discharge (Weeks 7–8)
Once your white blood cell counts recover and side effects are managed, you move toward the finish line.
- Evaluation: A day-28 PET-CT or bone marrow biopsy is performed to assess the initial response.
- Discharge: You receive a comprehensive English medical report and a 3-month follow-up plan before flying home.
Summary Timeline Table
| Phase | Duration | Primary Activity |
| Pre-Travel | 7–10 Days | Medical review & S2 Visa approval |
| Collection | 3–5 Days | Hospital admission & Leukapheresis |
| Manufacturing | 2–14 Days | Genetic cell modification in GMP lab |
| Recovery | 14–28 Days | Inpatient monitoring for CRS/safety |
